Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older, of any sex
• People who are able to understand and willing to sign a consent form
• People with a confirmed advanced solid tumour that has come back or stopped responding to treatment, and for whom no standard or approved treatment options remain
• People with classical Hodgkin lymphoma (a type of blood cancer) that has come back or stopped responding to at least 2 previous rounds of treatment
• People with an advanced solid tumour who have at least one tumour that can be measured on scans, according to standard research measurement guidelines
• People with classical Hodgkin lymphoma whose cancer can be measured or assessed for response to treatment
• People with a general health and activity level rated as 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activities) at the screening stage
• People who are able to provide a tumour tissue sample
• People with a life expectancy of at least 12 weeks

Who may not be able to join:

• People with a known allergy or sensitivity to any ingredient in the study drug HCB301
• People with active or untreated cancer spread to the brain or spinal fluid
• People who have had major surgery or intensive radiotherapy within the past 28 days, palliative (symptom-relieving) radiotherapy within the past 14 days, or a radioactive drug treatment within the past 56 days
• People with a significant heart or blood vessel condition
• People who still have side effects from previous cancer treatments that have not returned to a mild or baseline level (with the exception of hair loss and anaemia)
• People with a known inherited or acquired bleeding disorder
• People who have had a red blood cell transfusion within 4 weeks before the screening visit
• People diagnosed with a condition causing the body to destroy its own red blood cells (haemolytic anaemia or Evans Syndrome) in the past 3 months
• People who have received any other cancer treatment — either as part of another trial or as an approved therapy — within 21 days or within 5 half-lives of that treatment (whichever is shorter) before the start of this trial
• People currently using warfarin or similar blood-thinning medications (use of some other blood thinners may be considered on a case-by-case basis; low-dose aspirin of 100mg or less per day is permitted)
• People who have used herbal medicines within 14 days before the first dose of the study drug
• People who have previously received treatments targeting specific immune pathways known as SIRPα-CD47, PD-L1, or TGF-β (confirm with trial site)
• People who have had another cancer requiring active treatment within the past 2 years
• People who have used an investigational medical device within 28 days before the first dose of the study drug
• People who test positive for hepatitis B, active hepatitis C, HIV, or who have active or latent tuberculosis
• People with a known history of alcohol or drug misuse

Important: Always verify eligibility with the trial site directly before applying.